Goldman Sachs analyst Richard Law initiated coverage of Crinetics (CRNX) with a Neutral rating and $36 price target The sees the stock’s near-term value being meaningfully influenced by uncertainties of paltusotine’s and Crenessity’s launch performances given Crinetics’ lack of other meaningful pipeline catalysts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
- Crinetics Pharmaceuticals Presents at ENDO 2025 Meeting
- 3 Best Stocks to Buy Now, 6/30/2025, According to Top Analysts
- Crinetics Pharmaceuticals: Promising Pipeline and Strategic Focus Drive Buy Rating
- Crinetics Pharmaceuticals: Strategic Focus on Early-Stage Pipeline and Long-Term Value Creation Drives Buy Rating